Alkermes: Q3 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported third-quarter net income of $47.8 million, after reporting a loss in the same period a year earlier.
Source: qz.com
📰 Alkermes News
Page 20 - Alkermes News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alkermes. Real-time updates on events, politics, business and more.
Alkermes : Q3 2023 Earnings Call Prepared Remarks -October 25, 2023 at 09:02 am EDT
October 25, 2023 Alkermes Q3 2023 Earnings Conference Call Prepared Remarks Sandy Coombs: Welcome to the Alkermes plc...
Source: marketscreener.com
Alkermes: Q3 Earnings Snapshot -October 25, 2023 at 07:24 am EDT
DUBLIN — DUBLIN — Alkermes PLC on Wednesday reported third-quarter net income of $47.8 million, after reporting a loss in the same period a year earlier. On a per-share basis, the...
Source: marketscreener.com
Alkermes plc Reports Third Quarter 2023 Financial Results
— Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income...
United States Iain Brown Katie Joyce Company Reiterates Financial Expectations For Drug Administration Teva Pharmaceuticals United States Inc
Source: marketscreener.com
Why Alkermes Stock Is Sinking Today | The Motley Fool
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors.
Source: fool.com
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ:ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination wit...
United States Piper Sandler Greenbrier Companies Inc Lifesciences Inc Inmed Pharmaceuticals Inc Stratasys Ltd
Source: businessinsider.com
Alkermes' Orexin-2 Agonist Shows Promise for Narcolepsy
Alkermes announced initial results from a study evaluating its investigational orexin-2 receptor agonist in development for narcolepsy.
Craig Hopkinson Brendon Yee World Sleep Congress Woolcock Institute Of Medical Research Woolcock Institute Medical Research
Source: sleepreviewmag.com
Alkermes CEO Reflects on Living Company Purpose
Alkermes CEO Reflects on Living Company Purpose
United States Mental Health America Living Company Purpose News Network Platinum Bell Seal For Workplace Mental Health Living Company
Source: pr-inside.com
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone
Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment. The post Alkermes…
Source: biztoc.com
Alkermes (NASDAQ:ALKS) Earns Neutral Rating from Analysts at UBS Group
UBS Group began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report report published on Tuesday, Marketbeat Ratings reports. The firm issued a neutral rating and a $31.00 price target on the stock. A number of other equities research analysts have also weighed in on the company. StockNews.com lowered Alkermes from […]
Source: dailypolitical.com